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Abstract 
Activated microglia/macrophages have been implicated as key players in many central 
nervous system (CNS) diseases, such as brain tumor and Rett syndrome, in which they 
secrete regulatory/inflammatory cytokines that either suppress the local immune activity or 
lead to neurodegeneration, respectively. Polyamidoamine (PAMAM) dendrimers have been 
shown as promising nanodevices that specifically target activated microglia/macrophages in 
both brain tumor and Rett syndrome. Understanding the effects of dendrimer-drug conjugates 
on activated microglia/macrophages on a cellular level may provide guidance toward the 
improvement of in vivo efficacy in these diseases. Colony stimulating factor 1 (CSF1), 
mitogen-activated protein kinases (MAPKs) and glutaminase (GLS) are potential targets to 
modulate neuroinflammatory properties. In this study, we developed PAMAM dendrimer-
conjugated inhibitors against CSF1 receptor (D-BLZ945), MAPKs (D-PD98059) and GLS 
(D-JHU29), and tested the in vitro efficacies in different microglia cell lines, BV2 and/or 
Raw 264.7. D-BLZ945 and D-JHU29 did not exhibit cytotoxicity and had better or similar 
efficacy compared to free BLZ945 and JHU29. However, D-PD98059 didn’t demonstrate 
improved therapeutic effect compared to free PD98059. Given the ability of dendrimers to 
target activated microglia, D-BLZ945 and D-JHU29 may have improved potential for 
treating inflammation compared to free drugs. This study indicates that dendrimer conjugates 
have comparative efficacy to free drugs on cellular level with increased drug solubility. 
 
Advisor: Rangaramanujam Kannan, Ph.D. 
Thesis Committee: Rangaramanujam Kannan, Ph.D.; Laura Ensign, Ph.D.; Sujatha Kannan, 
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Chapter 1: Introduction 
1.1 PAMAM dendrimers as potent drug delivery vehicles 
Dendrimers are repetitively branched molecules that have been recently used as nanocarrier 
system for drug delivery.1 Polyamidoamine (PAMAM) dendrimers are a class of dendrimer 
with hyperbranched units of amide and amine. There are multiple properties that make 
dendrimers favorable delivery vehicles: (1) Small and controllable size: The sizes of most 
generations of PAMAM dendrimers are within nanoscale (1 to 10 nm in diameter) as shown 
in Figure 1. As the number of dendrimer generations or layers increases, dendrimer diameter 
increases about 1 nm per layer and the number of surface functional groups increases 
exponentially.2 MRI imaging shows that G = 3 to 9 PAMAM dendrimers sizes are in the 
range to preclude extravasation, making them great blood pool agents compared to 
Magnevist which completely excreted through kidney.3 (2) Modifiable surface functional 
groups: By varying terminal groups, dendrimers can be cationic (-NH2 terminated), neutral (-
OH terminated) or anionic (-COOH terminated). Dendrimers with different surface groups 
have distinct endocytosis mechanism and could target specific intracellular compartments.4 
Compared to linear poylmers, dendrimers have abundant surface reactive groups and high 
surface area to volume ratio, which make them promising carriers with high drug payload. 
They can be loaded with bioactive molecules either by covalent conjugation or encapsulation 
through inner void space.3  
(3) Biocompatibility: Dendrimer toxicity is associated with its size/generation and surface 
charge. Generally, PAMAM dendrimers with smaller size, neutral and anionic surface charge 
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would exhibit less toxic and lower permeation. PEG-layered PAMAM dendrimers are 
examples of biocompatible and degradable dendrimers which have enhanced permeation and 
retention (EPR).5,6,7 (4) Ability to overcome biological barrier and intrinsic property of 
targeting activated microglial cells. Evidence showed that PAMAM dendrimers could across 
the blood brain barrier (BBB) to deliver drug into malignant gliomas cells.8 Hydroxyl-
functionalized PAMAM dendrimers could selectively targeted in the injured neurons and 
brain microglia cells using systemic administration.9 Confocal imaging illustrates the rapid 
and selective distribution of dendrimer-Cy5 conjugates in solid brain tumor, followed by 
retention in tumor-associated microglia.10 Dendrimer has also shown to target activated 
microglia cells in injured mouse Retina upon intravitreal injection.11 These properties enable 
PAMAM dendrimers to be promising candidates for delivering unstable and hydrophobic 
drugs into central nervous system.  
 
Figure 1 Size and shape of PAMAM dendrimer from core to generation G=7. 2 
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1.2 Role and characterization of tumor associated macrophages (TAMs)  
Tumor associate macrophages (TAMs) are leukocyte population mainly found in the tumor 
microenvironment, contributing to tumor initiation, progression and metastasis.12 
Macrophages polarize into different functional forms in response to local cytokine signals. 
One widely accepted theory differentiates the distinct macrophage functional states into 
classically activated M1 phenotype and alternatively activated M2 phenotype.13 M1 
macrophages highly express pro-inflammatory cytokines, leading to pathogen killing, tissue 
damage and inflammation.14 In contrast, M2 macrophages secrete more anti-inflammatory 
cytokines, which are thought to facilitate neovascularization and tumor growth.15 There is no 
consensus on the relative importance of M1 and M2 macrophages in tumor development. At 
the tumor initiating stage, macrophages produce cytokines and growth factors such as 
interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ), generating 
chronic inflammatory responses.16 After tumors are established, the microenvironment turned 
from pro-inflammation into anti-inflammation. Macrophages are polarized by IL4 secreted 
from CD4+ T cells, as well as colony stimulating factor-1 (CSF1) and GM-CSF from tumor 
cells.16 
M1 and M2 phenotypes are featured by different signaling pathway activation and distinct 
expression level of surface receptors and cytokines. Stimulated by IFN-γ and LPS or TNF-α, 
M1 macrophages express higher level of IL-12, IL-23 and tumor necrosis factor (TNF). 13, 14 
M1 macrophages also up-regulate inducible nitric oxide synthase (iNOS) activation to 
release high concentration of nitric oxide (NO) (Figure 2).17 NO is considered to be a pro-
inflammatory agent due to its ability to induce inflammation and toxic reactions against 
infection and other tissues.18 By comparison, Immune complexes (ICs), IL4 and IL-13, IL-
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10, TGFβ and macrophage colony stimulating factor (MCSF) polarize macrophages to be M2 
phenotype.13, 14 M2 macrophages have high IL-10 expression and generate low level of IL-
12. Instead of iNOS activation, it is arginase pathway that predominates in the M2 subsets 
(Figure 2).19 High arginase 1(the liver isoform of arginase) production is a distinct feature 
for M2 macrophages. The up-regulation of arginase inhibits the translation of NO synthase 2 
(NOS2) mRNA.20 It halts the production of NO released by NOS2, which is a potential anti-
inflammatory mechanism 17. The increased Arginase 1 production is transcribed by STAT6, a 
downstream signaling molecule of IL4/IL-13 receptor pathway.21 
 
Figure 2 Key features for M1 and M2 macrophages.17, 19 
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1.3 CSF1/CSF1R pathway role in tumor 
CSF1, also called macrophage-colony stimulating factor (M-CSF), is a main hematopoietic 
cytokine regulating most macrophages and is significantly involved in the recruiting of 
macrophages into tumors by facilitating migration and survival.22 The activation of CSF1R 
stimulates gene expression and cytoskeletal remodeling, which leads to the mediation of 
target cell proliferation and differentiation.23 M2 type macrophages in primary tumors 
facilitate tumor cell invasion through an interaction involving tumor-secreted CSF1 and 
macrophage-synthesized EGF that mediates tumor migration along collagen fibers to blood 
vessels.16 The bind of CSF1 to its receptor (CSF1R) would activate the phosphorylation 
cascade of CSF1R and downstream molecules. One example is phosphorylating PIK3R1 that 
regulates phosphatidylinositol 3-kinase (PI3K), resulting in the activation of PI3K-Akt1 
signaling pathway.24 Activated CSF1R initiates the activation of the PI3K-Akt1 pathway, 
MAPK/ERK pathway and signal transducer and activator of transcription(STAT) family 
memberes STAT3, STAT5A and/or STAT5B.24  
Due to its critical role in regulating macrophages survival and activation (Figure 3), CSF1 is 
an important factor in innate immunity and is involved in the pathology underlying various 
diseases23. Evidences showed that the tumor infiltration process of CD8+ T cells was 
increased and the tumor growth rates in both mammary and cervical tumor model were 
attenuated after inhibiting CSF1/CSF1R pathway.25, 26 There are twelve clinical trials 
currently undergoing for therapeutic regents with the target of CSF1/CSF1R pathway in 
multiple cancers, such as breast carcinoma, leukemia, and glioblastoma.26 
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Figure 3 Role of CSF1 in polarization of TAMs. Monocyte differentiates into M1 or M2-like macrophage 
after receiving distinct signals. M1 subtype macrophages exhibit anti-tumor functions whereas M2 subtype 
macrophages exhibit pro-tumorigenic functions. Inhibition of CSF1R signaling reduces the recruitment of 
TAMs and halts the polarization of M2-like macrophages. 15 
1.4 MAPK pathway role in tumor and inflammation 
Mitogen-activated protein kinases (MAPKs) are essential enzymes for transducing signals 
from surface receptor to genes. This process initiates cellular responses to stimuli and 
mediates cell proliferation, differentiation and apoptosis.27 The MAPK cascades consist of 
MAPK, MAPK kinase (MAPKK or MEK) and MAPKK kinases (MAPKKK or MEKK). 
Phosphorylation of MAPK cascades and substrate proteins controls the activation of 
downstream transcription factors and cytoskeletal proteins.28 There are three well-
characterized subfamilies of MAPKs: the extracellular signal–regulated kinases (ERKs); the 
c-Jun NH2-terminal kinases (JNKs) and p38 enzymes. ERKs are essential in controlling cell 
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division and inhibitors of the ERK pathways are under clinical trials as potential anticancer 
agents.29 JNKs are critical regulators of transcription and cell apoptosis. JNKs inhibitors 
could promote the effect of chemotherapy in inhibiting tumor cell growth. The activation of 
p38 in immune cells is important in initiating immune response. 29 Considering the fact that 
ERK, JNK, and p38 pathways are all drug targets, inhibitors of MAPKs are promising drug 
candidates to treat inflammation, cancer and other diseases.29 MAPK pathway gets activated 
in macrophages in response to a variety of stimuli. LPS and tumor necrosis factor-α (TNF-α), 
for instance, are widely used agents to study MAPKs activation in macrophages. Both of LPS 
and TNF- α activate all three subfamilies of MAPKs.30 MAPKs stimulated by inflammatory 
cytokines and environmental stresses may be the mechanism underling diseases including 
asthma and autoimmunity 29. Evidence showed that anthrax lethal toxin inhibits MAPK 
activation in macrophages and interferes with the secretion of pro-inflammatory cytokines.31 
1.5 Glutaminase (GLS) role in neuroinflammation 
Glutaminase (GLS) is the enzyme localized in mitochondria accelerating the hydrolysis 
process of glutamine into glutamate and ammonia, which is an important energy source for 
rapidly proliferating cells like malignant tumor cells.32 It offers an efficient and alternative 
way to reprogram cancer cell metabolism under hypoxic conditions.33 In central nervous 
system, the overexpression of GLS in macrophages leads to the accumulation of glutamate, 
an important neurotransmitter. The up-regulated extracellular glutamate level is the 
mechanism underlying several inflammatory disorders like traumatic brain injury and HIV-1 
associated dementia.34, 35, 36 Glutamate released from activated microglia contributes to the 
neuron cells injury under inflammatory stimulation.37 GLS inhibitors could decrease 
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excessive extracellular glutamate and may be potential therapeutic agents against carcinoma 
and neuroinflammation.38 
1.6 Thesis overview 
This thesis focused on developing dendrimer mediated therapy for the treatment of 
glioblastoma and neuroinflammation. Specifically, we evaluated the therapeutic efficacy of 
dendrimer-drug conjugates on the molecular level. Small molecular drugs with low solubility 
can be conjugated to PAMAM dendrimer to generate highly soluble dendrimer drug 
therapeutics with similar or better efficacy compared to free drug in vitro with increased cell 
uptake. Colony stimulating factor 1 (CSF1), glutaminase (GLS) and Mitogen-activated 
protein kinases (MAPKs) are potential targets for modulating inflammation progression as 
described above. Inhibition to these targets might provide therapeutic opportunities in 
promoting the immunity in brain tumor, and attenuating neuroinflammation in Rett 
syndrome. The goal of this study is to investigate the potential therapeutic efficacy of 
dendrimer-drug conjugates for these diseases on activated microglia/macrophages (M1 or 
M2) at in vitro cellular level. I am trying to achieve this goal with three specific aims listed 
below. 
Specific Aim 1. Synthesize dendrimer-based nano-conjugates for targeting TAMs for more 
efficacious treatment in 9L glioblastoma model. CSF1 and MAPKs are important factors 
influencing macrophage polarization and tumor growth. Aiming to modulate TAMs 
phenotype in tumor microenvironment, CSF1 receptor inhibitor BLZ945 and MAPK 
pathway inhibitor PD98059 were conjugated to generation four PAMAM dendrimers 
(G4OH).  
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Specific Aim 2. Study the therapeutic efficacy of D-BLZ945 and D-PD98059 at the cellular 
level in vitro. BLZ945 was shown to reduce M2 phenotype cytokines expression in 
macrophage and had the potential to mediate macrophage polarization. Thus, I evaluated the 
in vitro efficacy of D-BLZ945 in affecting the production of arginase-1 in macrophages, a 
distinct feature for the M2 phenotype. On the other hand, PD98059 has been widely used as a 
potent inhibitor to MAPK signaling. Considering the role of MAPKs in pro-inflammatory 
polarization of macrophage, we assessed the efficacy of D-PD98059 by measuring the pro-
inflammatory cytokine expression level. 
Specific Aim 3. Evaluate D-JHU29 on its efficacy to inhibit glutaminase enzyme in vitro. 
JHU29 is a Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) analog 
which could inhibit human kidney-type glutaminase with IC50 of 2.7 µM. The inhibitory 
effect of D-JHU29 on extracellular glutamate levels is evaluated in Chapter 4.  
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Chapter 2: Design and synthesis of D-PD98059 and D-BLZ945 
conjugates 
2.1 Introduction  
Hydroxyl-terminated generation 4 PAMAM dendrimer (G4-OH) has favorable properties 
including small size (~4 nm), positive surface charge and ability to cross the blood brain 
barrier.9 We have shown the dendrimer conjugated N-acetylcysteine (NAC) can be 
specifically delivered to activated microglial cells in rabbit model of cerebral palsy without 
the help of targeting ligands.39 The dendrimer-NAC conjugate was also shown to have more 
efficacious anti-oxidant and anti-inflammatory effect in vitro.40 Through a fluorescence-
based quantification method, we showed that G4OH dendrimer accumulated in the brain 
tumor rapidly upon systemic administration and target TAMs gradually in a 9L gliosarcoma 
model.10 This targeted accumulation indicates that PAMAM G4OH dendrimer is a promising 
nano-vehicle in delivering immune-modulatory drugs to TAMs for the treatment of 
malignant gliomas.10 Based on these studies, we designed, synthesized D-PD98059 and D-
BLZ945 conjugates, and thoroughly characterized the physiochemical properties. 
PD98059 is a highly selective inhibitor for MAPK kinase (MEK) in MAPK pathway 
with IC50 of 2 µM in a cell-free assay.41 PD98059 inhibits MEK1 activation via Raf or MEK 
kinase (MEKK) with IC50 of 4 µM and inhibits MEK2 activation via Raf with IC50 of 50 
µM.41 PD98059 was also shown to inhibit the proliferation of murine macrophage 
RAW264.7 cells in the culture containing nuclear factor kappa B ligand (RANKL) in a dose-
dependent manner.42 However, PD98059 is poorly soluble in water or ethanol (<1 mg/mL). 
Even in DMSO, PD98059 has a low solubility (14 mg/mL) and requires heating for 
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solubilization. We envision the possibility that by conjugating PD98059 to the dendrimer, the 
solubility, targeting capability and therapeutic effect of the drug can be improved. D-
PD98059 conjugates were formulated with different synthetic schemes and aimed to 
attenuate the MEK pathways in macrophages.  
Besides MAPK pathway, another more specific target to modifying TAMs polarization is 
CSF1/CSF1R signaling.15 CSF1 expressed by tumor cells binds to the CSF1 receptor on the 
surface of TAMs, resulting in suppressing immune response at tumor sites.26,43 Several 
therapeutic agents targeting CSF1R are currently involved in clinical trials, including small 
molecule inhibitors PLX3397, ARRY-382 and JNJ-40346527 (Table 1).44 However, these 
small molecule inhibitors are not exclusively targeting CSF1R (Table 2).44,45 By comparison, 
BLZ945 is a highly potent, and selective inhibitor for Colony Stimulating Factor-1 Receptor 
(CSF1R), with ~ 1 nM IC50 concentrations in cell-free assay (Table 2).46 BLZ945 was shown 
to inactivate CSF1R phosphorylation and inhibits CSF1-dependent cell proliferation with 
EC50 of 67 nM.15,46 It hinders the CSF1/CSF1R signaling between macrophages and glioma 
cells and breaks the favorable growing environment for tumor by potentially repolarizing the 
tumor associate macrophages.16 CSF1R inhibition by BLZ945 is known to reduce tumor 
growth and progression in PDG mice (Mice expressing platelet-derived growth factor B 
(PDGFB) in glial progenitor cells), by reducing the M2 polarization and increasing the 
phagocytosis of TAMs.46 Evidences also showed that the tumor infiltration process of CD8+ 
T cells was increased and the tumor growth rates in both mammary and cervical tumor model 
were attenuated after inhibiting CSF-1/CSF-R pathway with BLZ945.26 However, BLZ945 
has poor solubility in water (<1 mg/mL). Despite the low IC50 value (1 nM) for BLZ945, 
large quantities of the BLZ945 (~ 200 mg/kg) were dosed orally daily to achieve the 
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therapeutic effect of this drug on the gliomas in PDG mice.46 We hypothesized that by 
conjugating BLZ945 drug to the dendrimer through a pH and esterase sensitive linker, we 
could improve the solubility, targeting capability and bioavailability of BLZ945.  
Compound/Class Target Clinical Phase Sponsor Tumor type 
PLX3397 






Solid tumors, Glioblastoma, 




/ small molecule 
















/ small molecule 
CSF1R I Johnson & Johnson 
 
Hodgkin lymphoma 
Table 1 Therapeutic agents targeting CSF1R in clinical trials. (mAB: monoantibody). 44 
EC50 PLX339
7 JNJ-40346527 ARRY-382 BLZ945 
CSF1R(c-fms) 20 nM 0.69 nM 9 nM 1 nM 
cKit 10 nM 5 nM nd 3880 nM 
PDGFRb nd nd nd 5860 nM 
PDGFRa  nd nd nd >10000 nM 
FIt3 160 nM 30 nM nd >10000 nM 
LCK 860 nM 88 nM nd >10000 nM 
VEGFR2(KD
R) 350 nM nd nd >10000 nM 
Table 2 Selectivity of small molecule to kinase. (nd=not disclosed). 45 
2.2 Materials and methods 
2.2.1 Materials 
Hydroxyl- polyamidoamine (PAMAM) dendrimer (64 G4-OH end groups) was obtained 
from Dendritech (Midland, MI, USA). BLZ945 was obtained from ChemShutle (Hayward, 
CA). PD98059 was purchased from selleckchem (Houston, TX). Succinic anhydride, glutaric 
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anhydride, Oxydiethylene bis(chloroformate), Methyl-4-chloro-4-oxobutanoate, 5-bromo 
pentanoic acid, triethylamine (TEA), dichloromethane (DCM), dimethyl formamide (DMF), 
N,N’-diisopropylethylamine (DIEA) were obtained from Sigma-Aldrich (St. Louis, MO, 
USA) in highest quality available. 3-(2-Pyridyldithio)propanoic Acid was obtained from  
Toronto Research Chemicals (Toronto, Canada). (Benzotriazol-1-yloxy)tripyrrolidino-
phosphonium hexafluorophosphate (PyBOP), DMAP and DCC were obtained from Bachem 
Americas Inc. (Torrance, CA,USA). Silica gel GF254 plates for Thin-layer chromatography 
(TLC) were purchased from Whatman (Piscataway, NJ). Proton NMR spectra were obtained 
using Bruker (500 MHz) spectrometer with DMSO-d6 solvent from Cambridge Isotope 
Laboratories, Inc. (Andover, MA). Proton chemical shifts were reported in ppm (d) and 
tetramethylsilane (TMS) was used as internal standard.  
2.2.2 Synthesis of D-PD98059 conjugate 
(1) Synthesis of PD98059 linker 
To generate the proper linker between PD98059 and PAMAM dendrimer, we tried different 
strategies to activate the aromatic amine functional handle.  
Reaction A: 
To the solution of PD98059 (25 mg, 0.0935 mmole) in DMF (10 mL), sodium hydride (2.24 
mg, 0.0935 mmole) was added and stirred for 5 min under nitrogen atmosphere, to this 
mixture 5-bromo pentanoic acid (18.6 mg, 0.1028 mmole) was added and stirred at room 
temperature for 24 h (Scheme 1). Adding isopropanol drop by drop at cold condition 
quenched the reaction mixture and then concentrating the reaction mixture via rotary 
evaporation. To this residue ethylacetate and water is added to extract organic components in 
ethylacetate. To this organic fraction sodium sulfate was added to remove any residual water 
fraction and supernatants were collected and concentrated by rotary evaporation. All the 
organic compounds from this method were separated via column chromatography and 
analyzed by NMR, according to NMR analysis, the intended product did not form this is 
attributed to poor reactivity of PD98059 aromatic amine.   
Scheme 1. Preparation of PD98059 carboxylate linker 
Reaction B: 
To the solution of PD98059 (25 mg, 0.0936 mmole) in dry THF at 0°C, add triethylamine 
and stir for 10 minutes under nitrogen atmosphere. Then add glutaric anhydride (10 mg, 
0.0936 mmole) dissolved in dry THF and stir for overnight, no product formation is observed 
according to TLC (Scheme 2). 
Scheme 2. Preparation of PD98059 glutarate linker 
Reaction C:
To the solution of PD98059 (25 mg, 0.0936 mmole) in dry THF at 0°C, added triethylamine 
























0.0936 mmole) dissolved in dry THF and stir for overnight, no product formation is observed 
according to TLC (Scheme 3).  
 
Scheme 3. Preparation of PD98059 succinate linker
Reaction D: 
PD98059 (10 mg, 0.0374 mmole) was dissolved in 10mL DCM and added triethylamine. 
Stirred for 10 minutes under nitrogen atmosphere. Then Methyl-4-chloro-4-oxobutanoate (10 
uL, 0.0748 mmole) was added into the DCM solution (Scheme 4). After 18 h, TLC showed 
no product formation. Thus we added half of original volume of Methyl-4-chloro-4-
oxobutanoate and triethylamine to the reaction and let it go for another 24 h. There was still 
no product formation. 
 
Scheme 4. Preparation of PD98059 methoxy ester linker 
Reaction E: 
To the solution of PD98059 (25 mg, 0.0935 mmole) in DCM at 0 °C DCC/DMAP were 

























mmole) was added slowly over a period of 5 min. The resulting reaction mixture was stirred 
for 24 h (Scheme 5). According to TLC no product formation was observed.  
Scheme 5. Preparation of PD98059 pyridyl disulfide linker
Reaction F: 
PD98059 (30 mg, 0.112 mmole) was dissolved in 10mL DCM and stired under nitrogen, 0°C 
for 10 minutes. Then ethylene-bis-choloroformate (200 uL, 1.122 mmole) was added drop by 
drop into the DCM solution. The reaction was done at 0°C for 24 h (Scheme 6). According 
to thin layer chromatography (TLC) all the starting material is consumed at this stage, we 
added silica gel (500 mg) to make slurry and performed column chromatography with ethyl 
acetate and hexanes to extract pure compound, PD98059 linker (yield 90%, 70.3mg).  
Scheme 6. Preparation of PD98059 chloroformate linker  
Among all the reactions for PD98059 linkers, PD98059 was consumed completely only in 
reaction F (Scheme 6) with ethylene-bis-chloroformate.  In reactions A, B, C and D, there were 
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urethane linker from reaction F was then treated with G4OH dendrimer to form the 
dendrimer-PD98059 conjugate.  
(2) Synthesis of dendrimer-PD conjugate 
To the solution of PD98059 urethane linker (3, Figure 4) (30 mg, 0.072 mmol) in DMF (15 
mL), added DIEA (38 uL, 0.215 mmol). Stirred under nitrogen atmosphere in an ice bath for 
20 minutes. Then hydroxyl PAMAM Dendrimer G4OH (4) (180 mg, 0.012 mmol) was added 
into the mixture and stirred for 48 h (Figure 4).  Silica gel was added into the flask to make 
slurry and column chromatography was performed with 3-5% Methanol in DCM to extract 
the pure compound D-PD98059 (5). After evaporated and re-dissolved the extracted portion, 
dialysis was performed in DMF (membrane MW cutoff = 2 kDa) for 48 h and the solvent 
was changed for 5 times. The obtained solution was evaporated under reduced pressure at 
room temperature, followed by high vacuum overnight, to obtain an semi-solid D-PD98059 
conjugates. The semi-solid conjugates were dissolved in DI water (0 ˚C) and dialyzed in DI 
water (membrane MW cutoff = 2 kDa) at 4 °C for 5 h, where changed the water every hour 
to get rid of DMF. The resultant water layer was lyophilized to get the powder of pure D-
PD98059 (5). The D-PD98059 (5) conjugates were characterized by 1H-NMR (Figure 5). 
2.2.3 Synthesis of D-BLZ945 conjugate 
(1) Synthesis of BLZ945-succinate linker 
BLZ945 (6) (100 mg, 0.25 mmol) was dissolved in DCM (25 mL) in 100 mL round 
bottomed flask under nitrogen atmosphere, to which triethylamine (210 uL, 1.5 mmol) was 
added. Stirred for 10 minutes and added succinic anhydride (7) (250 mg) that had dissolved 
in DCM (Scheme 8). Let the reaction go for 24 h and check TLC. The TLC results showed 
	   18	  
there were BLZ945 left in the system, and thus half of original amount of succinic anhydride 
and triethylamine were added to the reaction. After 8 h, all the starting material (BLZ945) 
was consumed at this stage according to TLC. We then added silica gel to make slurry and 
performed column chromatography with ~5% Methanol in DCM to extract pure compound, 
BLZ945-succinate linker (8) (120 mg, yield 95%). The BlZ945-succinate linker was 
characterized by 1H-NMR (A, Figure 7).  
(2) Synthesis of D-BLZ945 conjugate 
To the solution of BLZ945-succinate linker (120 mg, 0.24 mmol) in DMF (20 mL), added 
PyBOP (224.8 mg, 0.432 mmol) and DIEA (75uL, 0.432 mmol). The solution was stirred 
under nitrogen atmosphere in an ice bath for 20 minutes. Then hydroxyl PAMAM Dendrimer 
G4OH (4) (336 mg, 0.024 mmol) was added into the mixture and stirred for 48 h.  Silica gel 
was added into the flask to make slurry and column chromatography was performed with 3-
5% Methanol in DCM to extract the pure compound D-BLZ945 (9). After evaporated and re-
dissolved the extracted portion, dialysis was performed in DMF (membrane MW cutoff = 2 
kDa) for 48 h and the solvent was changed for 5 times. The obtained solution was evaporated 
under reduced pressure at room temperature, followed by high vacuum overnight, to obtain 
an orange semi-solid D-BLZ945 conjugates. The semi-solid conjugates were dissolved in DI 
water (0 ˚C) and dialyzed in DI water (membrane MW cutoff = 2 kDa) at 4 °C for 5 h, where 
changed the water every hour to get rid of DMF. The resultant water layer was lyophilized to 
get fluffy light yellow powder of pure D-BLZ945 (9). The structure of D-BlZ945 conjugate 
was characterized by 1H NMR (B, Figure 7). 
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2.2.4 High performance liquid chromatography (HPLC) characterization of the 
conjugates 
The purity of the D-BLZ945 conjugates was analyzed using HPLC (Waters Corporation, 
Milford, MA) with a 1525 binary pump, 2998 photodiode array (PDA) detector, 2475 
multiwavelength fluorescence detector and 717 auto sampler interfaced with Empower 
software. The HPLC chromatograms were monitored at 254 nm using PDA detector. The 
mobile phase was water/acetonitrile (0.1% w/w TFA). The column used for this study was 
symmetry c18 column, 300 A, 5 µM, 4.6 mm X 250 column with corresponding guard 
column. A gradient flow was used with the initial condition of 90:10 (Water/ACN) was 
maintained until 10 minutes and gradually changing to the ratio to 10:90 (Water/ACN) until 
30 min and then back to 90:10 for 20 min with flow rate of 1 mL/min for all conjugates. 
2.2.5 Dynamic light scattering (DLS) and zeta potential (ζ) 
The particle size and ζ-potential of D-BLZ945 conjugates were measured by dynamic light 
scattering (DLS) using a Zetasizer Nano ZS (Malvern Instrument Ltd. Worchester, UK) with 
a 50 mW HeNe laser (633 nm). The D-BLZ945 conjugates were dissolved in deionized water 
to make the solution with the final concentration of 0.1 mg/mL. The solution was filtered 
through a cellulose acetate membrane (0.45 µm, PALL Life Sciences) and DLS 
measurements were performed in triplicate, at 25 °C with a scattering angle of 173°.  
2.2.6 Drug release study  
The release of BLZ945 from the D-BLZ945 conjugates was determined in PBS (pH 7.4), 
Citrate buffer (pH 5.5). We chose these two buffers to simulate the extracellular condition 
(pH 7.4) and lysosomes (pH 5.5).  A concentration of 3 mg/mL was maintained at 37 ˚C in a 
Figure 4 Schematic representation of PD98059 urethane linker, 3 and D-PD98059 conjugate preparation. 
shaker. 600 μL solution was collected from the incubation mixture and frozen at -80 ˚C till 
the final analysis. The percent of released BLZ945 from DBLZ945 was quantified using 
HPLC (Figure 10).  
2.3 Results and discussion 
2.3.1 Synthesis of dendrimer-PD98059 (D-PD98059, 5) 
The drug molecule, PD98059 (1), has one aromatic amine functional handle; we attempted to 
functionalize this amine with carboxylic acid linkers (such as 4-hydroxy butanoic acid) to 
form corresponding amides, via multiple coupling chemistries (EDC/DMAP, DCC/DMAP 
and PyBOP/DIEA) and also by treating PD98059 with reactive acid chlorides to form amides 
with no success. Then, we switched our strategies (Figure 4) to make a PD98059 urethane 
linker (3) by treating PD98059 with Ethylene-bis-chloroformate (2). Following this strategy, 
we made PD98059 urethane linker (3) with reactive chloroformate, which upon treatment 
with hydroxyl terminal PAMAM dendrimer forms a dendrimer-PD98059 conjugate (D-
PD98059, 5). The characteristic peaks at 7.50 ppm and 8.0 ppm regions corresponded to D-
PD98059 (Figure 5). Unfortunately, this conjugate did not release PD98059 in various 
aqueous solutions (in the pH range of 2-12) or buffer conditions.  
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Figure 5 1H-NMR data for D-PD98059 conjugates 
 
2.3.2 Synthesis of dendrimer-BLZ945 conjugate (D-BLZ945, 9) 
 
Figure 6 Schematic representation of BLZ945 succinate linker, 8, and esterase cleavable D-BLZ945 conjugate, 
9, preparation.  
BLZ945 has primary hydroxyl functional group that acts as a good functional handle to form 
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BLZ945 (6) with succinate linker (7) to G4OH dendrimer (4) using a two-step synthesis 
strategy. BLZ945 (6) drug was treated with succinic anhydride (7) resulting in the formation 
of BLZ945-succinate linker (8). This compound 8 was treated with generation four hydroxyl 
terminal PAMAM dendrimer (4) to form pH and esterase sensitive D-BLZ945 conjugate (9, 
Figure 6). The conjugate 9 was extensively purified by dialysis and chromatographic 
techniques and its structure was confirmed by complementary techniques such as 1H-NMR, 
13C-NMR, HPLC, and MALDI analysis. From BLZ945 linker 1H-NMR (B, Figure 7), the 
characteristic peaks at 12.13 ppm region indicated the carboxylate linker formation and this 
was further supported by the presence of CH2 protons of succinate linker at 2.3 ppm. 
Similarly, D-BLZ945 conjugate formation was confirmed by the presence of amide protons 
of dendrimer at 7.96 ppm (C, Figure 7). According to NMR analysis, there was 
approximately 20% (w/w) drug loading per dendrimer.  
Figure 7 1H-NMR spectra of (A) BLZ945, (B) BLZ945-succinate linker and (C) G4OH D-BLZ945 conjugates. 
 
Aromatic and amide protons of BLZ945 (b) 
Cyclohexane  an methyl protons of BLZ945 (a & c) 
Aromatic and amide protons of BLZ945 (b) 
Carboxylic acid linker proton (d) 
Cyclohexane and linker protons (a & c) 
Aromatic and amide protons of BLZ945 and dendrimer (b) 
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2.3.3 HPLC characterization of D-BLZ945 conjugates 
D-BLZ945 conjugate, BLZ945-Succinate linker and BLZ945 were separated at least 3 
minutes using HPLC method. The purity of D-BLZ945 and BLZ945-Succinate linker were 
determined using reverse phase HPLC.  A gradient flow was used with the initial condition 
of 90:10 (Water/ACN) was maintained until 10 minutes and gradually changing to the ratio 
to 10:90 (Water/ACN) until 30 min and then back to 90:10 for 20 min with flow rate of 1 
mL/min for all conjugates. The HPLC data showed that free BLZ945 eluted at 16.7 min, 
BLZ945-Succinate linker eluted at 20.2 min and D-BLZ945 eluted at 49.4 min as a broad 
peak observed at 254 nm absorption (Figure 8). The broad peak of D-BLZ945 was a result 
of the molecular weight distribution of the conjugates, mainly from the different numbers of 
BLZ945 linked to each dendrimer. 
Figure 8 HPLC chromatograms of BLZ945 (16.735 min), BLZ945-succinate linker (20.216 min) and D-
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2.3.4 D-BLZ945 conjugate is small nanoparticle with positive surface charge. 
The size and zeta potential of D-BLZ945 conjugate was investigated. We synthesized two 
batches of D-BLZ945 in total. The size of D-BLZ945 was around 5.4 nm in the D-BLZ945 
conjugate with Mw of 16,200 and around 7.0 nm for D-BLZ945 with Mw of 19200. The zeta 
potential was (2.5 ± 0.1 mV) for the D-BLZ945 conjugates with Mw of 16,200 and (3.1 ± 0.3 
mV) for conjugates with Mw of 19,200 (Figure 9). The solubility of D-BLZ945 with Mw of 
19200 was 10 mg/mL in water, which was much higher than BLZ945 (almost insoluble in 
water).  
Batch Mw 
% loading of 
BLZ945 
# of BLZ945 
molecules 
Diameter (nm) ζ-potential 
1 ~16,200 8-10 % ~ 4 ~5.4 2.5 ± 0.1 mV 
2 ~19,200 18 – 20 % ~ 10 ~7.0 3.1 ± 0.3 mV 
Figure 9 Characterization of synthesized D-BLZ945 conjugates 
 
2.3.5 D-BLZ945 conjugates release free BLZ945 rapidly. 
We studied the release of drug from the conjugate by monitoring the release by HPLC 
technique. The release rate of BLZ945 from D-BLZ945 conjugates was investigated in PBS 
(pH 7.4) and citrate buffer (pH 5.5) to simulate the extracellular and lysosomes pH 
respectively. Calibration curves for BLZ945, BLZ945-Succinate linker and D-BLZ945 were 
established over a concentration of 1 ng to 1 mg at 254 nm, the limit of detection for the 
molecule was found to be at 10 ng. HPLC method was used to quantify the released BLZ945 
and BLZ945 linker and D-BLZ945 conjugate.  
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According to the HPLC results (Figure 10), over 80% BLZ945 released in 5 days at pH = 
5.0 and in 8 days at pH = 7.4, and the drug predominately released as free BLZ945. These 
drug release rates of D-BLZ945 were acceptable for delivering BLZ945 to TAMs in 
glioblastoma. Previous research showed that G4OH dendrimers were able to accumulated in 
the brain tumor from 15 min to 48 h upon systemic injection in a 9L gliosarcoma tumor 
model.10 Thus the rate that over 40% BLZ945 were released in 24 h at pH=5.0 would be 
sufficient for D-BLZ945 to exhibit the therapeutic efficacy of BLZ945 at the tumor site 
within 48 h. In current research of BLZ945, oral dose of 200 mg per kg body weight was 
used daily to achieve therapeutic effect.46 Considering the targeting ability of G4OH 
dendrimer, D-BLZ945 with these drug release rates would be able to potentially improve the 
bioavailability of BLZ945 with lower dose and less frequency. 
 
Figure 10 In vitro drug release rate of D-BLZ945 in PBS buffer (pH 7.4) and Citrate Buffer (pH 5.0). 
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2.4 Summary 
We developed D-PD98059 conjugates with urethane linker and D-BLZ945 conjugates with 
succinate linker. We tried multiple strategies to functionalize the aromatic amine in PD98059 
with carboxylic acid linkers with no success and turned to the strategy of making a PD98059 
urethane linker.  However, this D-PD98059 conjugate with urethane linker lack drug release 
up to 20 days. By contrast, D-BLZ945 conjugates with succinate linker have a release rate of 
free BLZ945 by over 90% within 10 days. D-BLZ945 conjugates have approximate 20% 
(w/w) drug loading and exhibit enhanced water solubility compared to free drug. The 
efficacy of D-BLZ945 was evaluated and shown in chapter 3. 
Chapter 3: In vitro evaluation of the therapeutic efficacy of D-
BLZ945 and D-PD98059 conjugates. 
3.1 Introduction 
Tumor associate macrophages (TAMs) play key roles in establishing the microenvironment 
for tumor growth and migration.47,48 Different phenotypes of macrophage are activated by 
distinct stimulating signals from T cells or tumor cells at different stages of tumor growth.19 
Many therapeutic methods have been explored to control tumor growth by targeting and 
modulating TAMs in malignant tumors like breast cancer and liver cancer.49,50,51 In response 
to the stimulations, polarized macrophages express cytokines to either promote inflammation 
or inhibit immune activity against carcinoma. Pro-inflammatory M1 type of macrophages is 
dominant at early stage of tumor initiation, generating cytokines and growth factors that help 
create chronic inflammation.52 Chronic inflammation is considered as a potential cause of 
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multiple cancers. M2 macrophages become dominant upon the establishment of tumor and 
create an anti-inflammatory environment to promote tumor growth.16 LPS, IFN-γ and TNF-α 
polarize macrophages to be M1 subtype, which is featured by high expression level of 
cytokines like IL1β, IL12 and TNF-α. On the other hand, IL4, TGFβ, IL10 and CSF1 could 
polarize macrophages to be M2 subtype, which is featured by high IL-10 expression, low IL-
12 expression and higher of arginase-1 production in cell.17, 19 
BLZ945, the CSF1R inhibitor, has shown to block the CSF1/CSF1R messaging between 
tumor cells and macrophages, which decreased M2 marker expression and hindered tumor 
growth.46 PD98059, the specific inhibitor for MAPK kinase, has the potential to inactivate 
MAPK pathway in M1 macrophages and inhibits pro-inflammatory response.30,41, 53 D-
BLZ945 and D-PD98059 have greater solubility than free drug and one dendrimer carry 
several free drugs that would increase the effective concentration in the targeting sites. We 
envision the better targeting ability, efficacy and biovialiability of the dendrimer conjugates.  
By investigating at the protein level of Arg-1 and the RNA level of pro-inflammatory 
cytokines (IL1β, IL6 and TNFα), I evaluated the potential therapeutic effect of D-BLZ945 
and D-PD98059 respectively and compared them to free drugs. The cytotoxicity of 
dendrimer conjugates and free drugs were also studied in this chapter. 
3.2 Materials and Method 
3.2.1 Cell culture for microglia and macrophage cells 
The BV2 mouse microglia cell line was from Children’s Hospital of Michigan Cell Culture 
Facility, and the Raw264.7 macrophage cell line was purchased from ATCC. Both of the 
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Life technologies) 
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with 5 % fetal bovine serum (FBS, Invitrogen) and 1% penicillin-streptomycin (P/S, 
Invitrogen) at 37 ˚C with 5% CO2 in an incubator. 
3.2.2 Preparation of BLZ945 and D-BLZ945 formulations for in vitro study 
BLZ945 was dissolve in DMSO to make a 1 mg/mL solution and D-BLZ945 (10% drug 
payload) was dissolved in medium containing 10% DMSO to make a 1 mg/mL solution. 
These solutions were diluted to the different concentrations with fresh DMEM medium. The 
conjugate concentrations were showed in terms of corresponding free drug concentrations in 
it. All the solutions were prepared freshly right before treatment. 
3.2.3 Preparation of PD98059 and D-PD98059 formulations for in vitro study 
PD98059 was dissolved in DMSO to make a 2 mg/mL solution and then diluted with media 
to different concentrations. D-PD98059 was dissolved in medium containing DMSO with 
same percentage as drug payload of the conjugate and diluted with fresh medium. The 
conjugate concentrations were showed in terms of corresponding free drug concentrations in 
it. 
3.2.4 Cytotoxicity studies 
BV2 cells were seeded in 96 well plates (Costar) with a concentration of 10,000 cells/well 
(100 µL/well) and incubated for 24 h. Then the cells were treated with culture medium 
containing different concentrations (10-9 to 10-5 g/mL) of BLZ945 and D-BLZ945 at 
increasing concentrations for 24 h. Cell viability was evaluated using alarmaBlue kit 
(Invitrogen). Absorbance at 600 nm and 570 nm were read using fluorescence microplate 
reader (BioTek Instruments). The cell viability was calculated using the equations given in 
the kit and normalized as percentage relative to control group.  
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The cytotoxicity of BLZ945 and D-BLZ945 on IL4 treated BV-2 and Raw264.7 cells were 
also measured. At 24 h after seeding (96 well plates, 10,000 cell/w seeding density), the cells 
were treated with fresh media containing experimental concentrations of BLZ945 and D-
BLZ945 (2, 20, 200 ng/mL) 1 h before adding IL4 (10 ng/mL) for 24 h co-treatment. Cell 
viability was measured in the same method described above. 
3.2.5 Western blot to analyze CSF1R activation and Arg1 expression levels 
BV2 cells were plated in 6 well plates with seeding density of 300,000 cells/well and 
cultured with phenol red free DMEM (10% FBS, 1% P/S). The cells treated with BLZ945, 
D-BLZ945 (2, 20 and 200 ng/mL) and DMSO as a control group for 2 h before adding IL4 
for 24 h co-treatment. For evaluating CSF1R activation, BV2 cells were treated with BLZ945 
or D-BLZ945 (20, 200 and 2000 ng/mL) 12 h before changing fresh media and stimulating 
with CSF1 for 30 min.  
The protein samples were harvested with 150 µL T-per buffer (ThermoFisher Scientific) 
containing Pierce EDTA-Free protease inhibitor (ThermoFisher Scientific) and sodium 
orthovanadate (Santa Cruz) as phosphatase inhibitor. Protein concentrations were determined 
using Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific). The proteins were 
separated on 10% SDS-PAGE gels (Biorad) at 120 V for about 1 hour and transferred to 
polyvinylidene fluoride membrane (PALL) at 80 V for 1 hour. The membranes were blocked 
with 5% w/v Bovine serum albumin (BSA) solution (Sigma-Aldrich) for 1 hour at room 
temperature. After primary antibody incubation on a rocker in cold room (4 ˚C) overnight, 
the membranes were placed in corresponding horseradish peroxidase (HRP) conjugated 
secondary antibody for 1 hour at room temperature. The protein bands were visualized using 
enhanced chemiluminescence (ECL) western blotting substrate (Promega Corporation) and 
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HyBlot CL autoradiography film (Denville Scientific Inc.). Quantitative densitometric 
analysis was performed using Multi Gauge software (Fujifilm).  
The following primary antibodies were used: Arginase-1 antibody (1:1000, #9819, Cell 
Signaling); phosphor-M-CSF Receptor (Tyr723) (49C10) antibody (1:1000, #3155 Cell 
Signaling); M-CSF Receptor antibody (1:1000, #3152, Cell Signaling); phosphor-Akt 
(Ser473) Antibody (1:1000, #9271, Cell Signaling); Akt (pan) (C67E7) antibody (1:1000, 
#4691, Cell Signaling) and β-actin (1:10,000, A5316, Sigma-Aldrich).  
3.2.6 RT-qPCR to analyze pro-inflammatory cytokine RNA levels 
BV2 cells were treated with LPS for 3 h, followed by free PD, D-PD and free dendrimer 
treatment with different doses for 6 and 24 h. Total RNA from cells was extracted using 
TriZol and 1ug RNA was reverse-transcribed into cDNA using High Capacity RNA-to 
cDNA kit (Applied Biosystems). The temperature profile was as follows: 37°C for 1 hour, 
95°C for 5 minutes and then 4°C for 1 hour. Then PCR amplification was quantified with 
Fast SYBR® Green Master Mix kit (Applied Biosystems). 
3.3 Results and Discussion 
3.3.1 In vitro efficacy of D-BLZ945 
 (1) Cytotoxicity of D-BLZ945 and BLZ945 on microglia and macrophage 
A cytotoxicity study was performed in BV2 microglia cells for D-BLZ945 conjugates and 
BLZ945 (Figure 11). BLZ945 is known as a highly potent inhibitor for CSF1R with 1 nM 
IC50 and 67 nM EC50 for bone marrow-derived macrophages (BMDMs).46 Thus 1 ng/mL was 
chosen as the lowest concentration and 10 µg/mL was chosen as the highest concentration 
which already contains 1% DMSO. BV2 cells were treated with BLZ945 and D-BLZ945 in a 
	   33	  
concentration range from 0.001 to 10 µg/mL for 24 h. The concentration of D-BLZ945 was 
shown in terms of equivalent concentrations of BLZ945. AlarmaBlue assay showed that D-
BLZ945 and BLZ945 didn’t show significant toxicity on BV2 cells cells up to 10 µg/mL 
after 24 h treatment (Figure 11). Because I was interested in investigating the effect of D-
BLZ945 on M2 subtype, the toxicities of D-BLZ945 and BLZ945 on IL4 activated microglia 
cells were also evaluated (Figure 12) to make sure the potential inhibitory efficacies in the 
following experiments are not from cell death. The concentrations of 2 ng/mL (5 nM), 20 
ng/mL (50 nM) and 200 ng/mL (500 nM) were chosen for this purpose. The results showed 
that D-BLZ945 and BLZ945 didn’t have significant toxicity to IL4 activated BV2 microglia 
cells after 24 h. D-BLZ945 exhibited higher cell viability in the highest concentration group 
(200 ng/mL) than BLZ945.  
 
Figure 11 Cytotoxicity of BLZ945 and D-BLZ945 on BV2 microglia cells. BV2 cells (P: 19) were treated with 
BLZ945 and D-BLZ945 (0.001, 0.01, 1 and 10 µg/mL) for 24 h. Cell viability was measured using alarmaBlue assay.  
n=6 independent replicates. 
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Figure 12 Cytotoxicity study of BLZ945 and D-BLZ945 on IL4 activated BV2 microglia cells. BV2 cells (P22) 
were treated with BLZ945 and D-BLZ945 (2, 20 and 200 ng/mL) one hour before adding IL4 for 24 h co-incubation. 
Cell viabilities were measured using alarmaBlue assay. n=6 independent replicates. 
By comparison, we measured the toxicity of D-BLZ945 and BLZ945 on another macrophage 
cell line Raw264.7 with IL4 stimulation (Figure 13). No significant toxicity was observed 
after 24 h for both BLZ945 and D-BLZ945.  
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Figure 13 Cytotoxicity study of BLZ945 and D-BLZ945 on IL4 activated Raw264.7 macrophages. Raw264.7 
macrophage cells (P: 3) were treated with BLZ945 and D-BLZ945 (2, 20 and 200 ng/mL) one hour before adding 
IL4 for 24 h co-incubation. Cell viability was measured using alarmaBlue assay. n=6 independent replicates. 
 
(2) Inhibitory effect of D-BLZ945 and BLZ945 on CSF1R phosphorylation 
BLZ945 is a potent CSF1R inhibitor with IC50 of 1 nM in a cell free assay.46 To evaluate the 
inhibitory effect of D-BLZ945 and BLZ945 on CSF1R, protein level of CSF1R activated 
form (phosphor-CSF1R) was measured after drug treatment on BV2 microglia cells (Figure 
14). The upper row was the western blot results and the lower row was the quantification of 
the upper graph by normalizing them to the control with arbitrary units. BV2 cells were 
treated with BLZ945 or D-BLZ945 for 12 h prior to 30 min stimulation with CSF1 (A, 
Figure 14). Up-regulated phosphor-CSF1R expression was observed following CSF-1 
stimulation, and it was effectively inhibited by D-BLZ945 and BLZ945. BLZ945 exhibited 
inhibitory effect on CSF1R phosphorylation at 20 ng/mL (50 nM). D-BLZ945 had 

















concentration dependent inhibitory effect and was similar efficacious than free BLZ945 at 
high concentration of 2000 ng/mL (5000 nM). The same trend was also observed after 24 h 
co-treatment of IL4 and D-BLZ945 or BLZ945 (B, Figure 14). This clearly indicates that D-
BLZ945 has therapeutic effect as the free drug.  
 
Figure 14 The inhibitory effect of D-BLZ945 on CSF1R phosphorylation in comparison to BLZ945. The upper 
row was the western blot results and the bottom row was the quantification of the upper graph by normalizing them to 
the control with arbitrary units. (A) BV2 cells were treated with BLZ945 or D-BLZ945 (20, 200 and 2000 ng/mL) for 
12 h prior to changed fresh media and stimulated with CSF1 for 30 minutes. n=3 independent replicates, * compared 
to CSF1 group, p<0.05. (B) BV2 cells were treated with BLZ945 or D-BLZ945 (20, 200 and 2000 ng/mL) for one 
hour before adding IL4 for 24 h co-incubation. 
(3) Inhibitory effect of D-BLZ945 and BLZ945 on IL4 stimulated Arg-1 expression 
Previous study showed that CSF1R suppression by BLZ945 reduces M2 macrophage 
polarization by decreasing M2 markers expression, which leads to the reprogram of tumor 
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microenvironment and inhibition of tumor growth.46 To investigate the anti-M2 phenotype 
effect of D-BLZ945 conjugate, we measured arginase-1 production. The up-regulated 
expression of arginase-1, a key feature for M2 macrophage, halts the production of NO via 
inhibiting NOS2 translation and thus initiates anti-inflammatory.17,20 In the preliminary 
study, BV2 cells were treated with IL4 (20ng/mL) for 6 h or 24 h (Figure 15). Upon 6 hour 
IL4 treatment, Arg-1 expression was increased and there was a significant increase in Arg-1 
expression after 24 h. A lower concentration of IL4 10ng/mL also significantly increased 
Arg-1 level after 24 h treatment. I further used 10 ng/mL to polarize BV2 cells in the 
following studies.  
Figure 15 IL4 stimulated Arg-1 expression. The top row was western blot results and the bottom row was the 
quantification analyses of the upper graphs. (A) BV2 cells were treated with IL4 (20 ng/mL) for 6 h and 24 h. 
(B) BV2 cells were treated with IL4 (10 ng/mL) for 24 h. n=3 independent replicates. ** p value <0.01. 
To study the inhibitory effect of D-BLZ945 and BLZ945 on IL4 induced Arg-1 expression, I
first treated cell with D-BLZ945 and BLZ945 for one hour to enable the uptake of drug. 
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Then IL4 (10 ng/mL) was added to the culture media to stimulate the M2 polarization. BV2 
cells were incubated with drug and IL4 for 24 h before collecting proteins. I measured the 
Arg-1 protein level using western blot. The results showed that D-BLZ945 and free BLZ945 
decrease Arg-1 production compared to IL4 treated positive control (Figure 16).  D-BLZ945 
and BLZ945 exhibited dose-dependent manner while no significant difference was observed 
between 20 ng/mL and 200 ng/mL treatment groups. D-BLZ945 showed more efficacious 
than BLZ945 in suppressing Arg-1 expression at the same concentration group. Also at the 
low concentration of 2 ng/mL, D-BLZ945 was observed to reduce Arg-1 level more than 
BLZ945 (Figure 17). G4OH dendrimer vehicle itself had no inhibitory effect. D-BLZ945 
seemed to have comparatively better inhibitory effect than free BLZ945. However, average 
from independent replicates didn’t show significant difference between D-BLZ945 and 
BLZ945.  
 
Figure 16 The inhibitory effect of D-BLZ945 and BLZ945 on IL4 induced Arg-1 expression. The top row was 
western blot results and the bottom row was the quantification analyses of the upper graphs. BV2 cells were 
treated with BLZ945 or D-BLZ945 (20 ng/mL and 200 ng/mL) for one hour before adding IL4 for 24 h co-
incubation. n=4 independent duplicates. ** p<0.01;  # compared to IL4 treatment group, p < 0.05.  
 
Figure 17 The inhibitory effect of D-BLZ945 and BLZ945 on IL4 induced Arg-1 at low concentration. 
BV2 cells were treated with BLZ945, D-BLZ945 or G4OH (2 ng/mL) for one hour before adding IL4 for 24 h co-
incubation. 

























3.3.2 In vitro efficacy of D-PD98059 
PD98059 is a selective inhibitor for MAPK pathway, which gets activated after pro-
inflammatory stimulation in macrophages.30, 41 To investigate the potential anti-inflammatory 
effect of PD98059 and D-PD98059, we evaluated the pro-inflammatory cytokines (IL1β, 
IL6, TNFα) expressions at mRNA level. Before drug treatment, we first used LPS to polarize 
BV2 cells to be pro-inflammatory phenotype and determined the appropriate treatment time 
of LPS. The result showed that 3 h LPS treatment is the best strategy in increasing the 
production of these pro-inflammatory cytokines (Figure 18). After adding LPS, the pro-
cytokine (IL1β, IL6) gene expressions increased dramatically and reached at peaks within 10 
h. After reaching peaks, the induction effect of LPS to the cytokines decreased rapidly in 12h 
and vanished slowly afterward. TNFα has the similar expression trend but less significant. 
Anti-inflammatory cytokines (IL4, IL10, TGFβ) levels were also measured (B, Figure 18). 
The expression levels were very low compared to pro-inflammatory cytokines after LPS 
treatment. 
 
Figure 18 The RNA level of pro-inflammatory cytokines (A) and anti-inflammatory cytokines (B) after LPS 
stimulation. BV2 cells were treated with LPS (100 ng/mL) and cell samples were collected after different time points to 
measure the cytokines levels. n=3 independent replicates. 
  
A B
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To study the effects of D-PD98059 on the pro-inflammatory cytokines, I activated BV2 cells 
with LPS for 3 h, following with free PD98059, D-PD98059 and free dendrimer treatment 
with different doses for 6 or 24 h (Figure 19). The results show that 3 h of LPS treatment 
(100 ng/mL) significantly increases the expression of IL1β and IL6 cytokine level. The 
expression level TNFα was not increased by LPS stimulation. 6 h treatment with lower dose 
PD98059 (0.2 µM) further up regulates the pro-inflammatory cytokine genes, while treatment 
with higher dose PD98059 (10 µM) significantly inhibited the increase of pro-inflammatory 
cytokines. This trend is reversed when cells are treated with same doses (on PD98059 base) 
of D-PD98059 for same time span (Top panel, Figure 19). Treatment of BV2 cells with D-
PD98059 using same doses showed different effects on the pro-inflammatory cytokine genes: 
low dose of D-PD98059 (0.2 µM) did not affect the pro-inflammatory cytokine genes, 
interestingly, increase the dose to 10 µM significantly up-regulated the pro-inflammatory 
cytokine genes. Treatment of BV2 cells with free dendrimer did not induce the increase of 
pro-inflammatory cytokine genes. This precludes the possibility of free dendrimer 
stimulating the pro-inflammatory cytokine gene regulation. For 24 h treatment group, similar 
trends are observed, however, as the effects of LPS treatment reduce almost to its original 
level, the influence of PD98059 and D-PD98059 treatment on LPS induced cytokine gene 
change reduces significantly compared with 6 h treatment group (Bottom panel, Figure 19). 
We couldn’t give a conclusive explanation for these unexpected data. Considering the low 
drug release rate of D-PD98059, this conjugate was not a good candidate for further study.  
Figure 19 The effect of PD98059 and D-PD98059 on pro-inflammatory cytokine RNA level. Treatment of 
LPS activates BV-2 cell line with PD98095 (displayed as PD in the figure for brevity) and dendrimer 
conjugated PD98095 (D-PD) for 6 h shows opposite dose response on pro-inflammatory cytokine expression. 
IL1β (left column), IL6 (middle column), TNFα (right column); Top panel: cytokine gene expression from 6 h 
treatment group, Bottom panel: cytokine gene expression from 24 h treatment group. n=3 independent replicates, 
* p<0.05 
3.4 Summary 
No significant toxicity was observed for D-BLZ945 conjugates and BLZ945 on IL4 activated 
microglia/macrophage cells. The CSF1R inhibition by D-BLZ945 and BLZ945 leads to the 
suppression of Arg-1 expression, which is a key feature for M2 macrophages (Figure 20). D-
BLZ945 exhibits dose-dependent inhibitory effect on CSF1R as free BLZ945 and shows 
comparatively better Arg-1 suppression efficacy. The inhibitory effect of D-BLZ945 on Arg-



















   
experiments in distinguishing the phenotype of microglia/macrophages via valuating more 
cytokine levels could be done to further investigate the potential effect of D-BLZ945 in 
modifying M2 macrophage polarization. Considering the intrinsic targeting ability of G4OH 
dendrimer to TAMs in the 9L gliosarcoma and the enhanced solubility,10 D-BLZ945 
conjugate would be a viable formulation for intracellular delivery of BLZ945 to TAMs and 
have improved therapeutic efficacy. The other dendrimer conjugate D-PD98059 didn’t show 
a clear therapeutic effect in the cellular level evaluation and was not good for further study 
considering its poor drug release rate. 
  
Figure 20 Diagrammatic representations of the mechanism action/hypothesis for in vitro efficacy study of D-
BLZ945 and BLZ945 on BV2 cells. 
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Chapter 4: In vitro evaluation of the therapeutic efficacy study of 
Dendrimer-JHU29 conjugates for Rett Syndrome (RTT) 
4.1 Introduction  
Rett Syndrome (RTT) is a neurological disorder that mainly affects female infants and is 
most caused by mutations in the methyl-CpG-binding protein 2 gene (MECP2) located on the 
X chromosome54. Inhibition of glutathione (GSH) in activated glial cells induces oxidative 
stress and underlies the pathogenesis and worsening of symptoms in RTT55, 56. More 
specifically, activated microglial cells (M1 phenotype) and astrocytes express pro-
inflammatory cytokines and initiate a neuroinflammation environment that leads to oxidative 
injury and increased glutamate expression. The excessive glutamate expression and reactive 
oxygen species in nervous system causes excitotoxicity and injuries to the CNS cells.57 Many 
therapeutic strategies have been developed to inhibit neurotoxic microglial activation, 
including the modulation of extracellular glutamate level by inhibiting microglial 
glutaminase.58,59  
Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide(BPTES) analogs are selective 
inhibitors of kidney-type GLS modified from insoluble BPTES molecule with multiple 
enhanced drug properties.38 JHU29 is a BPTES analog with similar GLS inhibitory potency 
compared to BPTES. JHU29 inhibits human kidney-type glutaminase with IC50 of 2.7 µM, 
while it showed no inhibition of mouse liver-type glutaminase (GLS2) up to 100 µM.38 Our 
lab developed dendrimer-JHU29 (D-JHU29) conjugates and the in vitro anti-glutaminase 
efficacy of D-JHU29 is evaluated in this chapter. I investigated the cytotoxicity of D-JHU29 
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on LPS activated microglia cells and measured the extracellular glutamate level to see the 
glutaminase suppression ability of D-JHU29. 
4.2 Methods and materials 
4.2.1 Preparation of JHU29 and D-JHU29 formulation for in vitro study 
JHU29 (1 mg) was first dissolved in 20 µL DMSO and then added into 980 µL medium to 
make a 1 mg/mL stock solution. DJHU29 (1 mg) was dissolved in 1 mL medium containing 
2 µL DMSO as a 1mg/mL stock solution. These stock solutions were then diluted with fresh 
phenol-red free DMEM medium into different concentrations for experiment use. The D-
JHU29 concentrations were showed in terms of corresponding free JHU29 concentrations in 
it. D-JHU29 formulations contain same percentage of DMSO as JHU29 in the same 
concentration groups. 
4.3.2 Cell culture for BV2 cells 
BV-2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Life 
technologies) with 5 % fetal bovine serum (FBS, Invitrogen) and 1% penicillin-streptomycin 
(P/S, Invitrogen) at 37 ˚C with 5% CO2 in an incubator. 
4.3.3 Cytotoxicity study of JHU29 and D-JHU29 
BV2 cells were seeded in 96 well plates with a concentration of 10,000 cells/well (100 
µL/well) and incubated for 24 h. Then the cells were treated with culture medium containing 
LPS (100 ng/mL) and different concentrations (1 µg/mL, 10 µg/mL and 50 µg/mL) of JHU29 
and D-JHU29 at increasing concentrations for 24 h. Cell viability was evaluated using MTS 
cell proliferation assay (Abcam). Absorbance at 490 nm was read using fluorescence 
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microplate reader (BioTek Instruments). The cell viability was calculated using the equations 
given in the kit and normalized as percentage relative to control group.  
4.3.4 Glutamate release study  
BV2 cells were treated with JHU29 or D-JHU29 (1 µg/mL, 10 µg/mL, 50 µg/mL) 30 minutes 
before adding LPS (100 ng/mL) for 24 hours co-treatment. Then supernatant were collected 
to measure extracellular glutamate concentration. The supernatants were collected and used 
to measure extracellular glutamate level. The glutamate level was evaluated using Amplex® 
Red Glutamic Acid/Glutamate Oxidase Assay Kit (Invitrogen). 
4.3 Results and discussion 
(1) Cytotoxicity of D-JHU29 and JHU29 on microglia and macrophage 
A cytotoxicity study of D-JHU29 and JHU29 was performed on BV2 microglia cells (Figure 
21). Because I was interested in investigating the anti-glutaminase effect of D-JHU29 on M1 
subtype that highly express glutamate, the toxicities of D-JHU29 and JHU29 on LPS 
activated microglia cells were evaluated to make sure the potential inhibitory efficacies in the 
following experiments are not from cell death. BV2 were treated with JHU29 or DJHU29 (1 
µg/mL, 10 µg/mL and 50µg/mL) 30 minutes before adding LPS (100 ng/mL) for 24 h co-
treatment. The results showed that D-JHU29 and JHU29 are non-toxic to LPS activated BV2 
microglia cells after 24 h treatment. The cells in D-JHU29 treatment groups showed higher 
viability than those in JHU29 treatment group. 
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Figure 21 Cytotoxicity of D-JHU29 and JHU29 on LPS activated BV2 cells. BV2 were treated with JHU29 or 
DJHU29 (1 µg/mL, 10 µg/mL, 50 µg/mL) 30 minutes before adding LPS (100 ng/mL) for 24 h co-treatment. n=6 
independent replicates. 
(2) The inhibitory effect of D-JHU29 and JHU29 in extracellular glutamate level 
The inhibitory effect of free JHU29 drug was first evaluated on BV2 microglia cells. The 
cells were treated with LPS (100 ng/mL) 30 minutes before adding JHU29 for 24 h co-
treatment. The results showed that JHU29 reduce extracellular glutamate level after LPS 
stimulation in a dose dependent manner. 50 µg/mL JHU29 could down-regulate the 
glutamate level back to control level.  
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Figure 22 The inhibitory effect of JHU29 on LPS stimulated glutamate expression. JHU29 were added to wells 
30 min before adding LPS (100ng/ml) for 24 h treatment. n=3 independent replicates. 
 
The inhibitory effect of D-JHU29 on extracellular glutamate level was then investigated in 
comparison to JHU29 (Figure 23). The results showed that D-JHU29 conjugates reduce LPS 
stimulated glutamate expression in a dose-dependent manner as JHU29. D-JHU29 and 
JHU29 of same concentration group had similar effect. It indicates that D-JHU29 was 
capable of lowering glutamate levels to the same magnitude as free JHU29 and thus had the 
similar therapeutic efficacy. Considering the targeting ability of G4OH dendrimer, we 
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Figure 23 The inhibitory effect of D-JHU29 and JHU29 on extracellular glutamate level. BV2 cells were treated 
with JHU29 or DJHU29 (1 µg/mL, 10 µg/mL, 50 µg/mL) 30 minutes before adding LPS (100 ng/mL) for 24 h co-
treatment. Then supernatant were collected to measure extracellular glutamate concentration. n=3 independent 
replicates. ***p<0.001; **p<0.01. 
 
4.4 Summary 
D-JHU29 is non-toxic to LPS activated microglia cells and the conjugates reduce LPS 
stimulated glutamate expression in a dose-dependent manner as JHU29. More direct methods 
to evaluate glutaminase activity may give better indication on its efficacy. Considering the 
targeting ability of G4OH dendrimer, we envision the better therapeutic effect of D-JHU29 in 
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Conclusion 
In this study, D-BLZ945 and D-PD98059 conjugates were successfully synthesized as 
potential therapeutic candidates for 9L glioblastoma disease model. The D-PD98059 
conjugate showed low drug release rate and didn’t have a clear in vitro therapeutic efficacy. 
By contrast, D-BLZ945 showed potent CSF1R inhibition and Arg-1 suppression effect and 
may be a promising therapeutic candidate for future study for glioblastoma disease model. D-
JHU29 exhibits similar anti-glutaminase efficacy to free JHU29 by measuring extracellular 
glutamate level. Considering the intrinsic targeting ability of dendrimers and enhanced 
solubility, dendrimer conjugates (D-BLZ945 and D-JHU29) may be viable formulations for 
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